Skip to main contentSkip to navigationSkip to search

Delivering better treatments

Camurus is committed to improving the lives of patients
with severe and chronic diseases

Read more

updates

Latest news

Disease areas

Focus on severe and chronic diseases

Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care

Learn more on disease areas

Events

Upcoming events


See all events

  • 14 Dec

    DNB Nordic Healthcare Conference

    Camurus is presenting at this conference in Oslo, Norway, 14 December, 2023. More information to come closer to the event.

    Add to calendar

  • 08 Jan

    SEB Nordic Seminar

    Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Copenhagen, 8 January at 2.00-2.40pm CET. The presentation can be seen by the conference participants.

    Add to calendar

  • 15 Feb

    Full Year Report 2023

    The full year report 2023 is published on 15 February 2024.

    Add to calendar

Products

Addressing important unmet medical needs

Learn about our products

Stories

Living with opioid dependence

Read Daniel's story

Annual General Meeting

Camurus’ Annual General Meeting 2024 will be held on Wednesday, 8 May 2024 at Elite Hotel Ideon in Lund, Sweden.

Shareholders who wish to have a matter dealt with at the AGM should, to ensure that the request can be considered, send such request to the Board of Directors (at the company’s address) no later than on 20 March 2024.

See more information on Camurus' general meetings
See documents from previous Ageneral meetings

Pipeline

Diversified pipeline with large potential

Camurus' innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

See pipeline

sustainability

Sustainable solutions for a healthier world

Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.

Learn more